Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9BZG2

UPID:
PPAT_HUMAN

ALTERNATIVE NAMES:
Acid phosphatase 4

ALTERNATIVE UPACC:
Q9BZG2; C0H3P7; Q9BZG3; Q9BZG4

BACKGROUND:
Acid phosphatase 4, with its alternative name Testicular acid phosphatase, is instrumental in the dephosphorylation of ERBB4, a process vital for inhibiting ligand-induced proteolytic cleavage. Its involvement in odontogenesis suggests a pivotal role in the development and formation of dental enamel.

THERAPEUTIC SIGNIFICANCE:
The protein's association with Amelogenesis imperfecta 1J, marked by hypoplastic enamel and enamel discolorization, underscores the therapeutic potential in addressing enamel formation defects. Exploring its function could lead to groundbreaking treatments for dental abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.